Demographics and disease characteristics at transplant for unweighted and weighted samples in the 8/8 HLA-MUD HCT cohort for the abatacept + CNI/MTX vs CNI/MTX comparison
| Characteristic . | Unweighted samples . | Weighted samples . | ||
|---|---|---|---|---|
| Abatacept + CNI/MTX (n = 71)∗ . | CNI/MTX (n = 355) . | Abatacept + CNI/MTX (n = 71)∗ . | CNI/MTX (n = 354) . | |
| Age, y | ||||
| Mean (SD) | 41.4 (19.5) | 51.4 (15.4) | 50.4 (16.0) | 50 (16.2) |
| Median (range) | 46 (6.9-71.9) | 54.4 (6.8-77.8) | 56.7 (6.9-71.9) | 53.1 (6.8-77.8) |
| Age category (y), n (%) | ||||
| ≤21 | 16 (22.5) | 11 (3.1) | 5.4 (7.7) | 15.9 (4.5) |
| >21 | 55 (77.5) | 344 (96.9) | 65.1 (92.3) | 338.2 (95.5) |
| Sex, n (%) | ||||
| Male | 40 (56.3) | 207 (58.3) | 36.5 (51.7) | 203.5 (57.5) |
| Female | 31 (43.7) | 148 (41.7) | 34.1 (48.3) | 150.5 (42.5) |
| Race, n (%) | ||||
| White | 64 (90.1) | 327 (92.1) | 63.6 (90.2) | 325.3 (91.9) |
| Black or African American | 3 (4.2) | 6 (1.7) | 3.7 (5.2) | 6.4 (1.8) |
| Asian | 3 (4.2) | 9 (2.5) | 2.6 (3.7) | 8.9 (2.5) |
| American Indian or Alaska Native | 1 (1.4) | 1 (0.3) | 0.6 (0.8) | 0.9 (0) |
| Not reported | 0 (0.0) | 12 (3.4) | 0 (0) | 12.6 (3.5) |
| Karnofsky/Lansky performance score, n (%)† | ||||
| 70 or 80 | 22 (31.0) | 131 (36.9) | 25.8 (36.5) | 126.8 (35.8) |
| 90 to 100 | 49 (69.0) | 224 (63.1) | 44.8 (63.5) | 227.3 (64.2) |
| Disease, n (%) | ||||
| AML | 29 (40.8) | 180 (50.7) | 37.5 (53.1) | 173.9 (49.1) |
| ALL | 24 (33.8) | 62 (17.5) | 14.1 (20.0) | 70.3 (19.8) |
| MDS or MDS/MPN unclassifiable‡ | 16 (22.5) | 83 (23.4) | 15.2 (21.6) | 83.3 (23.5) |
| CML | 1 (1.4) | 17 (4.8) | 2.7 (3.8) | 15.0 (4.2) |
| HL + NHL | 1 (1.4) | 13 (3.7) | 1.1 (1.5) | 11.6 (3.3) |
| Disease status, n (%)§ | ||||
| Early | 52 (73.2) | 235 (66.2) | 56.6 (80.3) | 234.0 (66.1) |
| Intermediate | 14 (19.7) | 54 (15.2) | 9.9 (14.0) | 57.4 (16.2) |
| Advanced | 4 (5.6) | 53 (14.9) | 3.0 (4.2) | 51.0 (14.4) |
| Chemo-sensitive | 1 (1.4) | 13 (3.7) | 1.1 (1.5) | 11.6 (3.3) |
| Chemo-resistant | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Conditioning intensity, n (%) | ||||
| Myeloablative | 59 (83.1) | 236 (66.5) | 51.6 (73.2) | 245.3 (69.3) |
| Reduced intensity or nonmyeloablative | 12 (16.9) | 119 (33.5) | 18.9 (26.8) | 108.8 (30.7) |
| Stem cell source, n (%) | ||||
| Bone marrow | 31 (43.7) | 72 (20.3) | 19.1 (27.0) | 84.8 (23.9) |
| Peripheral blood | 40 (56.3) | 283 (79.7) | 51.5 (73.0) | 269.3 (76.1) |
| CNI type, n (%) | ||||
| Tacrolimus | 59 (83.1) | 335 (94.4) | 65.7 (93.2) | 329.0 (92.9) |
| Cyclosporine | 12 (16.9) | 20 (5.6) | 4.8 (6.8) | 25.1 (7.1) |
| HCT-CI, n (%) | ||||
| 0 | 16 (22.5) | 69 (19.4) | 15.8 (22.5) | 74.3 (21.0) |
| 1 to 2 | 26 (36.6) | 104 (29.3) | 25.2 (35.8) | 100.2 (28.3) |
| ≥3 | 29 (40.8) | 182 (51.3) | 29.5 (41.8) | 179.5 (50.7) |
| Median (range) duration of follow-up, d|| | 1470 (575-2919) | 1181 (91-3001) | 1473 (575-2919) | 1361 (91-3019) |
| Characteristic . | Unweighted samples . | Weighted samples . | ||
|---|---|---|---|---|
| Abatacept + CNI/MTX (n = 71)∗ . | CNI/MTX (n = 355) . | Abatacept + CNI/MTX (n = 71)∗ . | CNI/MTX (n = 354) . | |
| Age, y | ||||
| Mean (SD) | 41.4 (19.5) | 51.4 (15.4) | 50.4 (16.0) | 50 (16.2) |
| Median (range) | 46 (6.9-71.9) | 54.4 (6.8-77.8) | 56.7 (6.9-71.9) | 53.1 (6.8-77.8) |
| Age category (y), n (%) | ||||
| ≤21 | 16 (22.5) | 11 (3.1) | 5.4 (7.7) | 15.9 (4.5) |
| >21 | 55 (77.5) | 344 (96.9) | 65.1 (92.3) | 338.2 (95.5) |
| Sex, n (%) | ||||
| Male | 40 (56.3) | 207 (58.3) | 36.5 (51.7) | 203.5 (57.5) |
| Female | 31 (43.7) | 148 (41.7) | 34.1 (48.3) | 150.5 (42.5) |
| Race, n (%) | ||||
| White | 64 (90.1) | 327 (92.1) | 63.6 (90.2) | 325.3 (91.9) |
| Black or African American | 3 (4.2) | 6 (1.7) | 3.7 (5.2) | 6.4 (1.8) |
| Asian | 3 (4.2) | 9 (2.5) | 2.6 (3.7) | 8.9 (2.5) |
| American Indian or Alaska Native | 1 (1.4) | 1 (0.3) | 0.6 (0.8) | 0.9 (0) |
| Not reported | 0 (0.0) | 12 (3.4) | 0 (0) | 12.6 (3.5) |
| Karnofsky/Lansky performance score, n (%)† | ||||
| 70 or 80 | 22 (31.0) | 131 (36.9) | 25.8 (36.5) | 126.8 (35.8) |
| 90 to 100 | 49 (69.0) | 224 (63.1) | 44.8 (63.5) | 227.3 (64.2) |
| Disease, n (%) | ||||
| AML | 29 (40.8) | 180 (50.7) | 37.5 (53.1) | 173.9 (49.1) |
| ALL | 24 (33.8) | 62 (17.5) | 14.1 (20.0) | 70.3 (19.8) |
| MDS or MDS/MPN unclassifiable‡ | 16 (22.5) | 83 (23.4) | 15.2 (21.6) | 83.3 (23.5) |
| CML | 1 (1.4) | 17 (4.8) | 2.7 (3.8) | 15.0 (4.2) |
| HL + NHL | 1 (1.4) | 13 (3.7) | 1.1 (1.5) | 11.6 (3.3) |
| Disease status, n (%)§ | ||||
| Early | 52 (73.2) | 235 (66.2) | 56.6 (80.3) | 234.0 (66.1) |
| Intermediate | 14 (19.7) | 54 (15.2) | 9.9 (14.0) | 57.4 (16.2) |
| Advanced | 4 (5.6) | 53 (14.9) | 3.0 (4.2) | 51.0 (14.4) |
| Chemo-sensitive | 1 (1.4) | 13 (3.7) | 1.1 (1.5) | 11.6 (3.3) |
| Chemo-resistant | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Conditioning intensity, n (%) | ||||
| Myeloablative | 59 (83.1) | 236 (66.5) | 51.6 (73.2) | 245.3 (69.3) |
| Reduced intensity or nonmyeloablative | 12 (16.9) | 119 (33.5) | 18.9 (26.8) | 108.8 (30.7) |
| Stem cell source, n (%) | ||||
| Bone marrow | 31 (43.7) | 72 (20.3) | 19.1 (27.0) | 84.8 (23.9) |
| Peripheral blood | 40 (56.3) | 283 (79.7) | 51.5 (73.0) | 269.3 (76.1) |
| CNI type, n (%) | ||||
| Tacrolimus | 59 (83.1) | 335 (94.4) | 65.7 (93.2) | 329.0 (92.9) |
| Cyclosporine | 12 (16.9) | 20 (5.6) | 4.8 (6.8) | 25.1 (7.1) |
| HCT-CI, n (%) | ||||
| 0 | 16 (22.5) | 69 (19.4) | 15.8 (22.5) | 74.3 (21.0) |
| 1 to 2 | 26 (36.6) | 104 (29.3) | 25.2 (35.8) | 100.2 (28.3) |
| ≥3 | 29 (40.8) | 182 (51.3) | 29.5 (41.8) | 179.5 (50.7) |
| Median (range) duration of follow-up, d|| | 1470 (575-2919) | 1181 (91-3001) | 1473 (575-2919) | 1361 (91-3019) |
Weighted samples were characterized using stabilized inverse probability of treatment weighing with propensity scores. Propensity scores were obtained from a logistic regression model including sex, disease, age, HCT graft source, conditioning intensity, Karnofsky/Lansky performance score, and CNI type as covariates.
Adapted from Kean et al.24,25
ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; HCT-CI, HCT-specific comorbidity index; HL, Hodgkin lymphoma; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; NHL, non-Hodgkin lymphoma; SD, standard deviation.
The abatacept + CNI/MTX group included 70 patients from the ABA2 clinical trial, and 1 patient treated outside of the trial.
MDS/MPN unclassifiable patient: n = 1 in abatacept group, n = 0 in non-abatacept group.
Two patients treated with abatacept in the ABA2 trial had reported performance scores of 80%; however, the performance score reported in the CIBMTR database for these patients was 70%. Because of the small number of patients treated with abatacept, these patients were included with performance score based on that reported from the ABA2 trial.
Chemotherapy-sensitive/chemotherapy-resistant distinction is specific to patients with lymphoma.
Duration of follow-up was defined as the date of transplant to the date of death or last follow-up. Median was estimated using the reverse Kaplan-Meier method; minimum and maximum values are summarized among patients who were alive at the end of follow-up.